Charles Edward (Ted) Hull II
Ted has over 25 years of experience in executive leadership positions within the clinical laboratory industry, including 15 years with Genova Diagnostics, a former FFC portfolio company. Under his leadership, Genova reached over $100 million in revenue, $30 million in EBITDA, and completed a successful sale to Levine Leichtman Capital Partners in 2013. Currently, Ted serves as CEO of Bako Diagnostics, a podiatry-focused clinical laboratory and products company.
Ted’s experience also includes stints at Eurofins Scientific, Quest Diagnostics, and Deloitte.